EUR/USD 1.1472 ▲ 0.07%GBP/USD 1.3383 ▲ 0.10%USD/JPY 157.4727 ▲ 0.05%USD/CHF 0.8208 ▼ 0.04%EUR/CHF 0.9414 ▲ 0.00%BTC/USD 85,758 ▼ 1.00%ETH/USD 2,732.85 ▼ 1.56%SOL/USD 117.31 ▼ 1.34%XAU/USD 4,355.49 ▲ 0.27%EUR/USD 1.1472 ▲ 0.07%GBP/USD 1.3383 ▲ 0.10%USD/JPY 157.4727 ▲ 0.05%USD/CHF 0.8208 ▼ 0.04%EUR/CHF 0.9414 ▲ 0.00%BTC/USD 85,758 ▼ 1.00%ETH/USD 2,732.85 ▼ 1.56%SOL/USD 117.31 ▼ 1.34%XAU/USD 4,355.49 ▲ 0.27%
Finance Review DailyMARKETS • BUSINESS • ECONOMY
EILMELDUNG
Brent crude breaches $100 as Middle East tensions compress Strait of Hormuz flows•European Stocks Slide After ECB Rate Hike as Oil Stays Above $100•PTC Therapeutics Completes Acquisition of Sangamo Gene Therapy Asset•Newcleo Completes SPAC Merger, Begins Nasdaq Trading•H2O America Approves Texas Wastewater Acquisition to Expand Service•Brent crude breaches $100 as Middle East tensions compress Strait of Hormuz flows•European Stocks Slide After ECB Rate Hike as Oil Stays Above $100•PTC Therapeutics Completes Acquisition of Sangamo Gene Therapy Asset•Newcleo Completes SPAC Merger, Begins Nasdaq Trading•H2O America Approves Texas Wastewater Acquisition to Expand Service•
ADVERTISEMENT
LIVE-DESK·Globale Marktredaktion·Last updated 14s ago
ADVERTISEMENT
Märkte/DevisenArticle

Novartis discontinues development of experimental ALS drug VHB937 (lifonebart) after mid-stage trial failure

Finance Review Daily is tracking this developing story; additional confirmed specifics had not been verified at the time of publication.

SL
Sophie Laurent · FX & Rates Desk · 22 Sept 2026 · 03:03 · 1 Min. Lesezeit
Teilen
Novartis discontinues development of experimental ALS drug VHB937 (lifonebart) after mid-stage trial failure

Novartis discontinues development of experimental ALS drug VHB937 (lifonebart) after mid-stage trial failure.

Euro / US Dollar

EURUSD
Full profile →
1.1474▲ 0.08%
As of 21/09/2026, 21:00:00

Finance Review Daily is tracking this development following a report from the original source. Additional confirmed specifics had not been verified at the time of publication.

Dieser Artikel wurde mit KI-Unterstützung erstellt und von einer Finances-Review-Redakteurin bearbeitet.
ADVERTISEMENT
Artikel teilen
SL
Geschrieben von
Sophie Laurent
FX & Rates Desk

Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.

Mehr von Sophie Laurent →
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets

Marktüberblick

Verzögert
EUR/USD1.1472▲ 0.07%GBP/USD1.3383▲ 0.10%USD/CHF0.8208▼ 0.04%BTC/USD85,758▼ 1.00%ETH/USD2,732.85▼ 1.56%XAU/USD4,355.49▲ 0.27%

Das könnte Sie auch interessieren

EU Approves Roche’s Susvimo for Neovascular AMD Treatment
Devisen

EU Approves Roche’s Susvimo for Neovascular AMD Treatment

Sophie Laurent · vor 15 Min.
ADVERTISEMENT